

# Global Nucleotide-based Therapeutics Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GEE9BFF598B6EN.html>

Date: October 2024

Pages: 158

Price: US\$ 3,400.00 (Single User License)

ID: GEE9BFF598B6EN

## Abstracts

### Report Overview

Nucleotide-based therapeutics offer huge potential to specifically modulate cellular pathways in ways not previously possible. These therapies include all nucleic-acid-based approaches that work inside cells to affect gene expression – the genetic blueprint of disease – to ultimately change protein expression and potentially alter the course of disease.

The global Nucleotide-based Therapeutics market size was estimated at USD 63950 million in 2023 and is projected to reach USD 88684.83 million by 2032, exhibiting a CAGR of 3.70% during the forecast period.

North America Nucleotide-based Therapeutics market size was estimated at USD 17737.25 million in 2023, at a CAGR of 3.17% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Nucleotide-based Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the

Global Nucleotide-based Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nucleotide-based Therapeutics market in any manner.

### Global Nucleotide-based Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

#### Key Company

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market Segmentation (by Type)

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Market Segmentation (by Application)

Neuromuscular Diseases

hATTR

COVID-19

Other

## Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

## Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Nucleotide-based Therapeutics Market

Overview of the regional outlook of the Nucleotide-based Therapeutics Market:

## Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

## Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

## Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Nucleotide-based Therapeutics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market

development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Nucleotide-based Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

- 1.1 Market Definition and Statistical Scope of Nucleotide-based Therapeutics
- 1.2 Key Market Segments
  - 1.2.1 Nucleotide-based Therapeutics Segment by Type
  - 1.2.2 Nucleotide-based Therapeutics Segment by Application
- 1.3 Methodology & Sources of Information
  - 1.3.1 Research Methodology
  - 1.3.2 Research Process
  - 1.3.3 Market Breakdown and Data Triangulation
  - 1.3.4 Base Year
  - 1.3.5 Report Assumptions & Caveats

### **2 NUCLEOTIDE-BASED THERAPEUTICS MARKET OVERVIEW**

- 2.1 Global Market Overview
  - 2.1.1 Global Nucleotide-based Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2032)
  - 2.1.2 Global Nucleotide-based Therapeutics Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

### **3 NUCLEOTIDE-BASED THERAPEUTICS MARKET COMPETITIVE LANDSCAPE**

- 3.1 Global Nucleotide-based Therapeutics Sales by Manufacturers (2019-2024)
- 3.2 Global Nucleotide-based Therapeutics Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Nucleotide-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Nucleotide-based Therapeutics Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Nucleotide-based Therapeutics Sales Sites, Area Served, Product Type
- 3.6 Nucleotide-based Therapeutics Market Competitive Situation and Trends
  - 3.6.1 Nucleotide-based Therapeutics Market Concentration Rate
  - 3.6.2 Global 5 and 10 Largest Nucleotide-based Therapeutics Players Market Share by Revenue

### 3.6.3 Mergers & Acquisitions, Expansion

## **4 NUCLEOTIDE-BASED THERAPEUTICS INDUSTRY CHAIN ANALYSIS**

### 4.1 Nucleotide-based Therapeutics Industry Chain Analysis

### 4.2 Market Overview of Key Raw Materials

### 4.3 Midstream Market Analysis

### 4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF NUCLEOTIDE-BASED THERAPEUTICS MARKET**

### 5.1 Key Development Trends

### 5.2 Driving Factors

### 5.3 Market Challenges

### 5.4 Market Restraints

### 5.5 Industry News

#### 5.5.1 New Product Developments

#### 5.5.2 Mergers & Acquisitions

#### 5.5.3 Expansions

#### 5.5.4 Collaboration/Supply Contracts

### 5.6 Industry Policies

## **6 NUCLEOTIDE-BASED THERAPEUTICS MARKET SEGMENTATION BY TYPE**

### 6.1 Evaluation Matrix of Segment Market Development Potential (Type)

### 6.2 Global Nucleotide-based Therapeutics Sales Market Share by Type (2019-2024)

### 6.3 Global Nucleotide-based Therapeutics Market Size Market Share by Type (2019-2024)

### 6.4 Global Nucleotide-based Therapeutics Price by Type (2019-2024)

## **7 NUCLEOTIDE-BASED THERAPEUTICS MARKET SEGMENTATION BY APPLICATION**

### 7.1 Evaluation Matrix of Segment Market Development Potential (Application)

### 7.2 Global Nucleotide-based Therapeutics Market Sales by Application (2019-2024)

### 7.3 Global Nucleotide-based Therapeutics Market Size (M USD) by Application (2019-2024)

### 7.4 Global Nucleotide-based Therapeutics Sales Growth Rate by Application

(2019-2024)

## **8 NUCLEOTIDE-BASED THERAPEUTICS MARKET CONSUMPTION BY REGION**

### 8.1 Global Nucleotide-based Therapeutics Sales by Region

#### 8.1.1 Global Nucleotide-based Therapeutics Sales by Region

#### 8.1.2 Global Nucleotide-based Therapeutics Sales Market Share by Region

### 8.2 North America

#### 8.2.1 North America Nucleotide-based Therapeutics Sales by Country

#### 8.2.2 U.S.

#### 8.2.3 Canada

#### 8.2.4 Mexico

### 8.3 Europe

#### 8.3.1 Europe Nucleotide-based Therapeutics Sales by Country

#### 8.3.2 Germany

#### 8.3.3 France

#### 8.3.4 U.K.

#### 8.3.5 Italy

#### 8.3.6 Russia

### 8.4 Asia Pacific

#### 8.4.1 Asia Pacific Nucleotide-based Therapeutics Sales by Region

#### 8.4.2 China

#### 8.4.3 Japan

#### 8.4.4 South Korea

#### 8.4.5 India

#### 8.4.6 Southeast Asia

### 8.5 South America

#### 8.5.1 South America Nucleotide-based Therapeutics Sales by Country

#### 8.5.2 Brazil

#### 8.5.3 Argentina

#### 8.5.4 Columbia

### 8.6 Middle East and Africa

#### 8.6.1 Middle East and Africa Nucleotide-based Therapeutics Sales by Region

#### 8.6.2 Saudi Arabia

#### 8.6.3 UAE

#### 8.6.4 Egypt

#### 8.6.5 Nigeria

#### 8.6.6 South Africa

## **9 NUCLEOTIDE-BASED THERAPEUTICS MARKET PRODUCTION BY REGION**

9.1 Global Production of Nucleotide-based Therapeutics by Region (2019-2024)

9.2 Global Nucleotide-based Therapeutics Revenue Market Share by Region (2019-2024)

9.3 Global Nucleotide-based Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Nucleotide-based Therapeutics Production

9.4.1 North America Nucleotide-based Therapeutics Production Growth Rate (2019-2024)

9.4.2 North America Nucleotide-based Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Nucleotide-based Therapeutics Production

9.5.1 Europe Nucleotide-based Therapeutics Production Growth Rate (2019-2024)

9.5.2 Europe Nucleotide-based Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Nucleotide-based Therapeutics Production (2019-2024)

9.6.1 Japan Nucleotide-based Therapeutics Production Growth Rate (2019-2024)

9.6.2 Japan Nucleotide-based Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Nucleotide-based Therapeutics Production (2019-2024)

9.7.1 China Nucleotide-based Therapeutics Production Growth Rate (2019-2024)

9.7.2 China Nucleotide-based Therapeutics Production, Revenue, Price and Gross Margin (2019-2024)

## **10 KEY COMPANIES PROFILE**

10.1 Sarepta Therapeutics

10.1.1 Sarepta Therapeutics Nucleotide-based Therapeutics Basic Information

10.1.2 Sarepta Therapeutics Nucleotide-based Therapeutics Product Overview

10.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Product Market Performance

10.1.4 Sarepta Therapeutics Business Overview

10.1.5 Sarepta Therapeutics Nucleotide-based Therapeutics SWOT Analysis

10.1.6 Sarepta Therapeutics Recent Developments

10.2 Ionis Pharmaceuticals

10.2.1 Ionis Pharmaceuticals Nucleotide-based Therapeutics Basic Information

10.2.2 Ionis Pharmaceuticals Nucleotide-based Therapeutics Product Overview

10.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Product Market

## Performance

10.2.4 Ionis Pharmaceuticals Business Overview

10.2.5 Ionis Pharmaceuticals Nucleotide-based Therapeutics SWOT Analysis

10.2.6 Ionis Pharmaceuticals Recent Developments

## 10.3 Alnylam

10.3.1 Alnylam Nucleotide-based Therapeutics Basic Information

10.3.2 Alnylam Nucleotide-based Therapeutics Product Overview

10.3.3 Alnylam Nucleotide-based Therapeutics Product Market Performance

10.3.4 Alnylam Nucleotide-based Therapeutics SWOT Analysis

10.3.5 Alnylam Business Overview

10.3.6 Alnylam Recent Developments

## 10.4 Biogen

10.4.1 Biogen Nucleotide-based Therapeutics Basic Information

10.4.2 Biogen Nucleotide-based Therapeutics Product Overview

10.4.3 Biogen Nucleotide-based Therapeutics Product Market Performance

10.4.4 Biogen Business Overview

10.4.5 Biogen Recent Developments

## 10.5 Nippon Shinyaku

10.5.1 Nippon Shinyaku Nucleotide-based Therapeutics Basic Information

10.5.2 Nippon Shinyaku Nucleotide-based Therapeutics Product Overview

10.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Product Market Performance

10.5.4 Nippon Shinyaku Business Overview

10.5.5 Nippon Shinyaku Recent Developments

## 10.6 Sobi

10.6.1 Sobi Nucleotide-based Therapeutics Basic Information

10.6.2 Sobi Nucleotide-based Therapeutics Product Overview

10.6.3 Sobi Nucleotide-based Therapeutics Product Market Performance

10.6.4 Sobi Business Overview

10.6.5 Sobi Recent Developments

## 10.7 Novartis

10.7.1 Novartis Nucleotide-based Therapeutics Basic Information

10.7.2 Novartis Nucleotide-based Therapeutics Product Overview

10.7.3 Novartis Nucleotide-based Therapeutics Product Market Performance

10.7.4 Novartis Business Overview

10.7.5 Novartis Recent Developments

## 10.8 BioNTech

10.8.1 BioNTech Nucleotide-based Therapeutics Basic Information

10.8.2 BioNTech Nucleotide-based Therapeutics Product Overview

10.8.3 BioNTech Nucleotide-based Therapeutics Product Market Performance

- 10.8.4 BioNTech Business Overview
- 10.8.5 BioNTech Recent Developments
- 10.9 Pfizer
  - 10.9.1 Pfizer Nucleotide-based Therapeutics Basic Information
  - 10.9.2 Pfizer Nucleotide-based Therapeutics Product Overview
  - 10.9.3 Pfizer Nucleotide-based Therapeutics Product Market Performance
  - 10.9.4 Pfizer Business Overview
  - 10.9.5 Pfizer Recent Developments
- 10.10 Moderna Therapeutics
  - 10.10.1 Moderna Therapeutics Nucleotide-based Therapeutics Basic Information
  - 10.10.2 Moderna Therapeutics Nucleotide-based Therapeutics Product Overview
  - 10.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Product Market Performance
  - 10.10.4 Moderna Therapeutics Business Overview
  - 10.10.5 Moderna Therapeutics Recent Developments
- 10.11 Jazz Pharmaceuticals
  - 10.11.1 Jazz Pharmaceuticals Nucleotide-based Therapeutics Basic Information
  - 10.11.2 Jazz Pharmaceuticals Nucleotide-based Therapeutics Product Overview
  - 10.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Product Market Performance
  - 10.11.4 Jazz Pharmaceuticals Business Overview
  - 10.11.5 Jazz Pharmaceuticals Recent Developments
- 10.12 CureVac
  - 10.12.1 CureVac Nucleotide-based Therapeutics Basic Information
  - 10.12.2 CureVac Nucleotide-based Therapeutics Product Overview
  - 10.12.3 CureVac Nucleotide-based Therapeutics Product Market Performance
  - 10.12.4 CureVac Business Overview
  - 10.12.5 CureVac Recent Developments
- 10.13 Regulus Therapeutics
  - 10.13.1 Regulus Therapeutics Nucleotide-based Therapeutics Basic Information
  - 10.13.2 Regulus Therapeutics Nucleotide-based Therapeutics Product Overview
  - 10.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Product Market Performance
  - 10.13.4 Regulus Therapeutics Business Overview
  - 10.13.5 Regulus Therapeutics Recent Developments
- 10.14 ProQR
  - 10.14.1 ProQR Nucleotide-based Therapeutics Basic Information
  - 10.14.2 ProQR Nucleotide-based Therapeutics Product Overview
  - 10.14.3 ProQR Nucleotide-based Therapeutics Product Market Performance

- 10.14.4 ProQR Business Overview
- 10.14.5 ProQR Recent Developments
- 10.15 Secarna
  - 10.15.1 Secarna Nucleotide-based Therapeutics Basic Information
  - 10.15.2 Secarna Nucleotide-based Therapeutics Product Overview
  - 10.15.3 Secarna Nucleotide-based Therapeutics Product Market Performance
  - 10.15.4 Secarna Business Overview
  - 10.15.5 Secarna Recent Developments
- 10.16 MiNA Therapeutics
  - 10.16.1 MiNA Therapeutics Nucleotide-based Therapeutics Basic Information
  - 10.16.2 MiNA Therapeutics Nucleotide-based Therapeutics Product Overview
  - 10.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Product Market Performance
  - 10.16.4 MiNA Therapeutics Business Overview
  - 10.16.5 MiNA Therapeutics Recent Developments
- 10.17 Sylentis
  - 10.17.1 Sylentis Nucleotide-based Therapeutics Basic Information
  - 10.17.2 Sylentis Nucleotide-based Therapeutics Product Overview
  - 10.17.3 Sylentis Nucleotide-based Therapeutics Product Market Performance
  - 10.17.4 Sylentis Business Overview
  - 10.17.5 Sylentis Recent Developments
- 10.18 Arrowhead
  - 10.18.1 Arrowhead Nucleotide-based Therapeutics Basic Information
  - 10.18.2 Arrowhead Nucleotide-based Therapeutics Product Overview
  - 10.18.3 Arrowhead Nucleotide-based Therapeutics Product Market Performance
  - 10.18.4 Arrowhead Business Overview
  - 10.18.5 Arrowhead Recent Developments
- 10.19 Silence Therapeutics
  - 10.19.1 Silence Therapeutics Nucleotide-based Therapeutics Basic Information
  - 10.19.2 Silence Therapeutics Nucleotide-based Therapeutics Product Overview
  - 10.19.3 Silence Therapeutics Nucleotide-based Therapeutics Product Market Performance
  - 10.19.4 Silence Therapeutics Business Overview
  - 10.19.5 Silence Therapeutics Recent Developments
- 10.20 Dicerna
  - 10.20.1 Dicerna Nucleotide-based Therapeutics Basic Information
  - 10.20.2 Dicerna Nucleotide-based Therapeutics Product Overview
  - 10.20.3 Dicerna Nucleotide-based Therapeutics Product Market Performance
  - 10.20.4 Dicerna Business Overview

10.20.5 Dicerna Recent Developments

## **11 NUCLEOTIDE-BASED THERAPEUTICS MARKET FORECAST BY REGION**

11.1 Global Nucleotide-based Therapeutics Market Size Forecast

11.2 Global Nucleotide-based Therapeutics Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Nucleotide-based Therapeutics Market Size Forecast by Country

11.2.3 Asia Pacific Nucleotide-based Therapeutics Market Size Forecast by Region

11.2.4 South America Nucleotide-based Therapeutics Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Consumption of Nucleotide-based Therapeutics by Country

## **12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)**

12.1 Global Nucleotide-based Therapeutics Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Nucleotide-based Therapeutics by Type (2025-2032)

12.1.2 Global Nucleotide-based Therapeutics Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Nucleotide-based Therapeutics by Type (2025-2032)

12.2 Global Nucleotide-based Therapeutics Market Forecast by Application (2025-2032)

12.2.1 Global Nucleotide-based Therapeutics Sales (K MT) Forecast by Application

12.2.2 Global Nucleotide-based Therapeutics Market Size (M USD) Forecast by Application (2025-2032)

## **13 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. Nucleotide-based Therapeutics Market Size Comparison by Region (M USD)
- Table 5. Global Nucleotide-based Therapeutics Sales (K MT) by Manufacturers (2019-2024)
- Table 6. Global Nucleotide-based Therapeutics Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global Nucleotide-based Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global Nucleotide-based Therapeutics Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleotide-based Therapeutics as of 2022)
- Table 10. Global Market Nucleotide-based Therapeutics Average Price (USD/MT) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers Nucleotide-based Therapeutics Sales Sites and Area Served
- Table 12. Manufacturers Nucleotide-based Therapeutics Product Type
- Table 13. Global Nucleotide-based Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Nucleotide-based Therapeutics
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Nucleotide-based Therapeutics Market Challenges
- Table 22. Global Nucleotide-based Therapeutics Sales by Type (K MT)
- Table 23. Global Nucleotide-based Therapeutics Market Size by Type (M USD)
- Table 24. Global Nucleotide-based Therapeutics Sales (K MT) by Type (2019-2024)
- Table 25. Global Nucleotide-based Therapeutics Sales Market Share by Type (2019-2024)
- Table 26. Global Nucleotide-based Therapeutics Market Size (M USD) by Type (2019-2024)

- Table 27. Global Nucleotide-based Therapeutics Market Size Share by Type (2019-2024)
- Table 28. Global Nucleotide-based Therapeutics Price (USD/MT) by Type (2019-2024)
- Table 29. Global Nucleotide-based Therapeutics Sales (K MT) by Application
- Table 30. Global Nucleotide-based Therapeutics Market Size by Application
- Table 31. Global Nucleotide-based Therapeutics Sales by Application (2019-2024) & (K MT)
- Table 32. Global Nucleotide-based Therapeutics Sales Market Share by Application (2019-2024)
- Table 33. Global Nucleotide-based Therapeutics Sales by Application (2019-2024) & (M USD)
- Table 34. Global Nucleotide-based Therapeutics Market Share by Application (2019-2024)
- Table 35. Global Nucleotide-based Therapeutics Sales Growth Rate by Application (2019-2024)
- Table 36. Global Nucleotide-based Therapeutics Sales by Region (2019-2024) & (K MT)
- Table 37. Global Nucleotide-based Therapeutics Sales Market Share by Region (2019-2024)
- Table 38. North America Nucleotide-based Therapeutics Sales by Country (2019-2024) & (K MT)
- Table 39. Europe Nucleotide-based Therapeutics Sales by Country (2019-2024) & (K MT)
- Table 40. Asia Pacific Nucleotide-based Therapeutics Sales by Region (2019-2024) & (K MT)
- Table 41. South America Nucleotide-based Therapeutics Sales by Country (2019-2024) & (K MT)
- Table 42. Middle East and Africa Nucleotide-based Therapeutics Sales by Region (2019-2024) & (K MT)
- Table 43. Global Nucleotide-based Therapeutics Production (K MT) by Region (2019-2024)
- Table 44. Global Nucleotide-based Therapeutics Revenue (US\$ Million) by Region (2019-2024)
- Table 45. Global Nucleotide-based Therapeutics Revenue Market Share by Region (2019-2024)
- Table 46. Global Nucleotide-based Therapeutics Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)
- Table 47. North America Nucleotide-based Therapeutics Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Nucleotide-based Therapeutics Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Nucleotide-based Therapeutics Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Nucleotide-based Therapeutics Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Sarepta Therapeutics Nucleotide-based Therapeutics Basic Information

Table 52. Sarepta Therapeutics Nucleotide-based Therapeutics Product Overview

Table 53. Sarepta Therapeutics Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Sarepta Therapeutics Business Overview

Table 55. Sarepta Therapeutics Nucleotide-based Therapeutics SWOT Analysis

Table 56. Sarepta Therapeutics Recent Developments

Table 57. Ionis Pharmaceuticals Nucleotide-based Therapeutics Basic Information

Table 58. Ionis Pharmaceuticals Nucleotide-based Therapeutics Product Overview

Table 59. Ionis Pharmaceuticals Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Ionis Pharmaceuticals Business Overview

Table 61. Ionis Pharmaceuticals Nucleotide-based Therapeutics SWOT Analysis

Table 62. Ionis Pharmaceuticals Recent Developments

Table 63. Alnylam Nucleotide-based Therapeutics Basic Information

Table 64. Alnylam Nucleotide-based Therapeutics Product Overview

Table 65. Alnylam Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. Alnylam Nucleotide-based Therapeutics SWOT Analysis

Table 67. Alnylam Business Overview

Table 68. Alnylam Recent Developments

Table 69. Biogen Nucleotide-based Therapeutics Basic Information

Table 70. Biogen Nucleotide-based Therapeutics Product Overview

Table 71. Biogen Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Biogen Business Overview

Table 73. Biogen Recent Developments

Table 74. Nippon Shinyaku Nucleotide-based Therapeutics Basic Information

Table 75. Nippon Shinyaku Nucleotide-based Therapeutics Product Overview

Table 76. Nippon Shinyaku Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 77. Nippon Shinyaku Business Overview

Table 78. Nippon Shinyaku Recent Developments

Table 79. Sobi Nucleotide-based Therapeutics Basic Information

Table 80. Sobi Nucleotide-based Therapeutics Product Overview

Table 81. Sobi Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 82. Sobi Business Overview

Table 83. Sobi Recent Developments

Table 84. Novartis Nucleotide-based Therapeutics Basic Information

Table 85. Novartis Nucleotide-based Therapeutics Product Overview

Table 86. Novartis Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Novartis Business Overview

Table 88. Novartis Recent Developments

Table 89. BioNTech Nucleotide-based Therapeutics Basic Information

Table 90. BioNTech Nucleotide-based Therapeutics Product Overview

Table 91. BioNTech Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. BioNTech Business Overview

Table 93. BioNTech Recent Developments

Table 94. Pfizer Nucleotide-based Therapeutics Basic Information

Table 95. Pfizer Nucleotide-based Therapeutics Product Overview

Table 96. Pfizer Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. Pfizer Business Overview

Table 98. Pfizer Recent Developments

Table 99. Moderna Therapeutics Nucleotide-based Therapeutics Basic Information

Table 100. Moderna Therapeutics Nucleotide-based Therapeutics Product Overview

Table 101. Moderna Therapeutics Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Moderna Therapeutics Business Overview

Table 103. Moderna Therapeutics Recent Developments

Table 104. Jazz Pharmaceuticals Nucleotide-based Therapeutics Basic Information

Table 105. Jazz Pharmaceuticals Nucleotide-based Therapeutics Product Overview

Table 106. Jazz Pharmaceuticals Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. Jazz Pharmaceuticals Business Overview

Table 108. Jazz Pharmaceuticals Recent Developments

Table 109. CureVac Nucleotide-based Therapeutics Basic Information

Table 110. CureVac Nucleotide-based Therapeutics Product Overview

Table 111. CureVac Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD),

Price (USD/MT) and Gross Margin (2019-2024)

Table 112. CureVac Business Overview

Table 113. CureVac Recent Developments

Table 114. Regulus Therapeutics Nucleotide-based Therapeutics Basic Information

Table 115. Regulus Therapeutics Nucleotide-based Therapeutics Product Overview

Table 116. Regulus Therapeutics Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 117. Regulus Therapeutics Business Overview

Table 118. Regulus Therapeutics Recent Developments

Table 119. ProQR Nucleotide-based Therapeutics Basic Information

Table 120. ProQR Nucleotide-based Therapeutics Product Overview

Table 121. ProQR Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 122. ProQR Business Overview

Table 123. ProQR Recent Developments

Table 124. Secarna Nucleotide-based Therapeutics Basic Information

Table 125. Secarna Nucleotide-based Therapeutics Product Overview

Table 126. Secarna Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 127. Secarna Business Overview

Table 128. Secarna Recent Developments

Table 129. MiNA Therapeutics Nucleotide-based Therapeutics Basic Information

Table 130. MiNA Therapeutics Nucleotide-based Therapeutics Product Overview

Table 131. MiNA Therapeutics Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 132. MiNA Therapeutics Business Overview

Table 133. MiNA Therapeutics Recent Developments

Table 134. Sylentis Nucleotide-based Therapeutics Basic Information

Table 135. Sylentis Nucleotide-based Therapeutics Product Overview

Table 136. Sylentis Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 137. Sylentis Business Overview

Table 138. Sylentis Recent Developments

Table 139. Arrowhead Nucleotide-based Therapeutics Basic Information

Table 140. Arrowhead Nucleotide-based Therapeutics Product Overview

Table 141. Arrowhead Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 142. Arrowhead Business Overview

Table 143. Arrowhead Recent Developments

- Table 144. Silence Therapeutics Nucleotide-based Therapeutics Basic Information
- Table 145. Silence Therapeutics Nucleotide-based Therapeutics Product Overview
- Table 146. Silence Therapeutics Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 147. Silence Therapeutics Business Overview
- Table 148. Silence Therapeutics Recent Developments
- Table 149. Dicerna Nucleotide-based Therapeutics Basic Information
- Table 150. Dicerna Nucleotide-based Therapeutics Product Overview
- Table 151. Dicerna Nucleotide-based Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 152. Dicerna Business Overview
- Table 153. Dicerna Recent Developments
- Table 154. Global Nucleotide-based Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
- Table 155. Global Nucleotide-based Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
- Table 156. North America Nucleotide-based Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
- Table 157. North America Nucleotide-based Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
- Table 158. Europe Nucleotide-based Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
- Table 159. Europe Nucleotide-based Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
- Table 160. Asia Pacific Nucleotide-based Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
- Table 161. Asia Pacific Nucleotide-based Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
- Table 162. South America Nucleotide-based Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
- Table 163. South America Nucleotide-based Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
- Table 164. Middle East and Africa Nucleotide-based Therapeutics Consumption Forecast by Country (2025-2032) & (Units)
- Table 165. Middle East and Africa Nucleotide-based Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
- Table 166. Global Nucleotide-based Therapeutics Sales Forecast by Type (2025-2032) & (K MT)
- Table 167. Global Nucleotide-based Therapeutics Market Size Forecast by Type

(2025-2032) & (M USD)

Table 168. Global Nucleotide-based Therapeutics Price Forecast by Type (2025-2032) & (USD/MT)

Table 169. Global Nucleotide-based Therapeutics Sales (K MT) Forecast by Application (2025-2032)

Table 170. Global Nucleotide-based Therapeutics Market Size Forecast by Application (2025-2032) & (M USD)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Product Picture of Nucleotide-based Therapeutics
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Nucleotide-based Therapeutics Market Size (M USD), 2019-2032
- Figure 5. Global Nucleotide-based Therapeutics Market Size (M USD) (2019-2032)
- Figure 6. Global Nucleotide-based Therapeutics Sales (K MT) & (2019-2032)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Nucleotide-based Therapeutics Market Size by Country (M USD)
- Figure 11. Nucleotide-based Therapeutics Sales Share by Manufacturers in 2023
- Figure 12. Global Nucleotide-based Therapeutics Revenue Share by Manufacturers in 2023
- Figure 13. Nucleotide-based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Nucleotide-based Therapeutics Average Price (USD/MT) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Nucleotide-based Therapeutics Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Nucleotide-based Therapeutics Market Share by Type
- Figure 18. Sales Market Share of Nucleotide-based Therapeutics by Type (2019-2024)
- Figure 19. Sales Market Share of Nucleotide-based Therapeutics by Type in 2023
- Figure 20. Market Size Share of Nucleotide-based Therapeutics by Type (2019-2024)
- Figure 21. Market Size Market Share of Nucleotide-based Therapeutics by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Nucleotide-based Therapeutics Market Share by Application
- Figure 24. Global Nucleotide-based Therapeutics Sales Market Share by Application (2019-2024)
- Figure 25. Global Nucleotide-based Therapeutics Sales Market Share by Application in 2023
- Figure 26. Global Nucleotide-based Therapeutics Market Share by Application (2019-2024)
- Figure 27. Global Nucleotide-based Therapeutics Market Share by Application in 2023
- Figure 28. Global Nucleotide-based Therapeutics Sales Growth Rate by Application

(2019-2024)

Figure 29. Global Nucleotide-based Therapeutics Sales Market Share by Region

(2019-2024)

Figure 30. North America Nucleotide-based Therapeutics Sales and Growth Rate

(2019-2024) & (K MT)

Figure 31. North America Nucleotide-based Therapeutics Sales Market Share by

Country in 2023

Figure 32. U.S. Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) &

(K MT)

Figure 33. Canada Nucleotide-based Therapeutics Sales (K MT) and Growth Rate

(2019-2024)

Figure 34. Mexico Nucleotide-based Therapeutics Sales (Units) and Growth Rate

(2019-2024)

Figure 35. Europe Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024)

& (K MT)

Figure 36. Europe Nucleotide-based Therapeutics Sales Market Share by Country in

2023

Figure 37. Germany Nucleotide-based Therapeutics Sales and Growth Rate

(2019-2024) & (K MT)

Figure 38. France Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024)

& (K MT)

Figure 39. U.K. Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) &

(K MT)

Figure 40. Italy Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) &

(K MT)

Figure 41. Russia Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024)

& (K MT)

Figure 42. Asia Pacific Nucleotide-based Therapeutics Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Nucleotide-based Therapeutics Sales Market Share by Region in

2023

Figure 44. China Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) &

(K MT)

Figure 45. Japan Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) &

(K MT)

Figure 46. South Korea Nucleotide-based Therapeutics Sales and Growth Rate

(2019-2024) & (K MT)

Figure 47. India Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) &

(K MT)

Figure 48. Southeast Asia Nucleotide-based Therapeutics Sales and Growth Rate

(2019-2024) & (K MT)

Figure 49. South America Nucleotide-based Therapeutics Sales and Growth Rate (K MT)

Figure 50. South America Nucleotide-based Therapeutics Sales Market Share by Country in 2023

Figure 51. Brazil Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Nucleotide-based Therapeutics Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Nucleotide-based Therapeutics Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Nucleotide-based Therapeutics Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Nucleotide-based Therapeutics Production Market Share by Region (2019-2024)

Figure 62. North America Nucleotide-based Therapeutics Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Nucleotide-based Therapeutics Production (K MT) Growth Rate (2019-2024)

Figure 64. Japan Nucleotide-based Therapeutics Production (K MT) Growth Rate (2019-2024)

Figure 65. China Nucleotide-based Therapeutics Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Nucleotide-based Therapeutics Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Nucleotide-based Therapeutics Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Nucleotide-based Therapeutics Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Nucleotide-based Therapeutics Market Share Forecast by Type (2025-2032)

Figure 70. Global Nucleotide-based Therapeutics Sales Forecast by Application (2025-2032)

Figure 71. Global Nucleotide-based Therapeutics Market Share Forecast by Application (2025-2032)

## I would like to order

Product name: Global Nucleotide-based Therapeutics Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GEE9BFF598B6EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEE9BFF598B6EN.html>